Background: Metabolic syndrome (MetS) and its components have been acknowledged as risk factors for a single cardiometabolic disease, but their relationship with the risk of cardiometabolic multimorbidity is unclear. The present study aimed to prospectively investigate the association of MetS and its components with the risk of cardiometabolic multimorbidity.Methods: In this prospective cohort study, we analyzed data of 353,427 participants from the UK Biobank. Participants with a previous diagnosis of cardiometabolic disease or those with missing data on the items of MetS were not eligible. Cardiometabolic multimorbidity was defined as the co-existence of two and more conditions of type 2 diabetes, coronary heart disease (CHD), and stroke. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the relationship between MetS, components of MetS and cardiometabolic multimorbidity. Results: During a median of 8.9 years of follow-up, 3389 participants developed the cardiometabolic multimorbidity. Compared with individuals without MetS, individuals with MetS had a three times higher risk of developing cardiometabolic multimorbidity (adjusted HR: 3.02, 95% CI: 2.82-3.24). The accumulation of MetS components was associated, in a dose-response manner, with the risk of cardiometabolic multimorbidity (P for trend <0.0001). For the temporal sequences in the development of cardiometabolic diseases, the corresponding HRs (95% CIs) for individuals with ≥4 metabolic abnormalities were 1.57 (1.47-1.68) for cardiovascular disease only, 10.27 (7.62-13.84) for cardiovascular disease with subsequent diabetes, 25.34 (21.95-29.24) for diabetes only, and 42.97 (21.19-87.13) for diabetes with subsequent cardiovascular disease.Conclusions: MetS was independently associated with the risk of cardiometabolic multimorbidity, and the risk substantially increased with a greater number of MetS components. Our findings highlight the importance of screening and treatment of MetS in the prevention of cardiometabolic multimorbidity.